Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 October 2013

 

London, GB (October 25, 2013) – This press release provides an overview of the opinions adopted at the September 2013 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.

 

 

Three new medicines recommended for approval

 

This month, the CHMP recommended the approval of Opsumit, an orphan medicine intended for the treatment of pulmonary arterial hypertension in adults.

 

The Committee gave a positive recommendation for Brintellix in the treatment of major depressive episodes in adults.

 

The generic medicine Levetiracetam Hospira also received a positive opinion for use in epilepsy.

 

In the field of epilepsy, the CHMP also recommended switching the marketing authorisation for the orphan medicine Diacomit from a conditional to a full approval. Diacomit is used in children with a very rare type of epilepsy called ‘severe myoclonic epilepsy in infancy’ (SMEI), also known as Dravet’s syndrome. In 2007, the European Commission granted a conditional marketing authorisation for Diacomit on the basis of a CHMP positive opinion. Conditional marketing authorisations are granted for medicines that are likely to have a significant benefit for patients, before all of the formal studies on its efficacy and safety have been completed. As the company has now supplied the additional information necessary, the CHMP has recommended switching from conditional to full approval.

 

Conditional marketing authorisations are one of the mechanisms put in place by the Agency to facilitate market access for medicines that fulfill unmet medical needs.

 

 

Five new extensions of indication

 

The CHMP recommended granting extensions of indications to Cimzia and Eviplera as well as for three vaccines, Synflorix, Vepacel and Pandemic Influenza Vaccine Baxter H5N1.

 

 

Compassionate-use programme for sofosbuvir

 

The CHMP gave an opinion on the conditions under which early access through compassionate-use programmes could be given for sofosbuvir specifically for patients with chronic hepatitis C virus (HCV) infection before or after liver transplantation. More information is available in a separate press release.

 

 

Outcome of safety reviews

 

The CHMP issued recommendations on the use of intravenous nicardipine.

 

The Committee has also confirmed its previously recommended changes to the use of metoclopramide-containing medicines as well as to the use of the ergot derivative dihydroergotoxine.

 

 

Review of product information underway for Iclusig

 

Following the emergence of new data on the risk of arterial thrombosis with Iclusig (ponatinib), the Committee concluded that the product information for prescribers and patients should be reviewed and amended if appropriate to include information and warnings on this risk. A formal procedure is currently underway to implement this update.

 

 

Election of vice-chair of CHMP

 

The CHMP has also elected his new vice-chair, Dr Pierre Demolis, for a three-year mandate. Pierre Demolis, a cardiologist by training, is currently Director of the oncology and haematology division at the French Medicines Agency (ANSM). He has been a member of the CHMP since 2007.

 

 

 


European Medicines Agency, 25.10.2013 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…